This 63 gene panel is used for investigation of myeloid neoplasms and myelodysplastic syndromes.
The Myeloid gene panel offers comprehensive testing for genomic variants that can provide diagnostic and prognostic information for patients with myeloid neoplasms and myelodysplastic syndromes. It is based on international guidelines and best practices. If required, customisation to suit individual patient needs can be offered.
Myeloid Gene Panel
For diagnostic/prognostic work-up of AML/MDS.
ABL1, ANKRD26, ARID1A, ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CREBBP, CSF3R, CUX1, CXCR4, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MPL, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PIM1, PPM1D, PTEN, PTPN11, RAD21, RHOA, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, STAT6, TET2, TP53, U2AF1, WT1 and ZRSR2
Next generation sequencing
4 weeks
Please contact 1800 822 999 if not Medicare eligible.
Haematology genetics test request form preferred. Standard pathology request form accepted.
Blood 4mL EDTA tube or Bone Marrow 4mL EDTA tube
Blood or bone marrow
Specialist/consultant physician request only
